126 related articles for article (PubMed ID: 2853934)
1. The clinical and endocrine assessment of three different antiandrogen regimens combined with a very long-acting gonadotrophin-releasing hormone analogue.
Waxman J; Williams G; Sandow J; Hewitt G; Abel P; Farah N; Fleming J; Cox J; O'Donoghue EP; Sikora K
Am J Clin Oncol; 1988; 11 Suppl 2():S152-5. PubMed ID: 2853934
[TBL] [Abstract][Full Text] [Related]
2. Influence of different types of antiandrogens on luteinizing hormone-releasing hormone analogue-induced testosterone surge in patients with metastatic carcinoma of the prostate.
Schulze H; Senge T
J Urol; 1990 Oct; 144(4):934-41. PubMed ID: 2144596
[TBL] [Abstract][Full Text] [Related]
3. Combination of a GnRH agonist with an antiandrogen or bromocriptine in the treatment of prostatic cancer; slight potentiation of antigonadal effects.
Huhtaniemi I; Parvinen M; Venho P; Rannikko S
Int J Androl; 1991 Oct; 14(5):374-86. PubMed ID: 1839022
[TBL] [Abstract][Full Text] [Related]
4. Short-term anti-androgen therapy and very long-acting depot gonadotrophin-releasing hormone agonist for prostatic cancer.
Waxman J
Prog Clin Biol Res; 1989; 303():61-8. PubMed ID: 2528741
[No Abstract] [Full Text] [Related]
5. Metastatic cancer of the prostate managed with buserelin versus buserelin plus cyproterone acetate.
Schroeder FH; Lock TM; Chadha DR; Debruyne FM; Karthaus HF; de Jong FH; Klijn JG; Matroos AW; de Voogt HJ
J Urol; 1987 May; 137(5):912-8. PubMed ID: 2952810
[TBL] [Abstract][Full Text] [Related]
6. Rat prostatic weight regression in reaction to ketoconazole, cyproterone acetate, and RU 23908 as adjuncts to a depot formulation of gonadotropin-releasing hormone analogue.
Lamberts SW; Uitterlinden P; de Jong FH
Cancer Res; 1988 Nov; 48(21):6063-8. PubMed ID: 2844399
[TBL] [Abstract][Full Text] [Related]
7. Combination treatment in M1 prostate cancer.
Ferrari P; Castagnetti G; Ferrari G; Pollastri CA; Tavoni F; Dotti A
Cancer; 1993 Dec; 72(12 Suppl):3880-5. PubMed ID: 8252509
[TBL] [Abstract][Full Text] [Related]
8. Treatment of prostatic cancer by monthly injections of an LHRH-analogue depot.
Hjertberg H; Varenhorst E; Svensson M; Kågedal B; Nordenskjöld B
Acta Oncol; 1988; 27(4):361-4. PubMed ID: 2974290
[TBL] [Abstract][Full Text] [Related]
9. Short-term versus long-term addition of cyproterone acetate to buserelin therapy in comparison with orchidectomy in the treatment of metastatic prostate cancer. European Organization for Research and Treatment of Cancer--Genitourinary Group.
Klijn JG; de Voogt HJ; Studer UE; Schröder FH; Sylvester R; De Pauw M
Cancer; 1993 Dec; 72(12 Suppl):3858-62. PubMed ID: 8252504
[TBL] [Abstract][Full Text] [Related]
10. Advanced prostatic cancer: clinical and hormonal response to flutamide in patients pretreated with LHRH analogue and cyproterone acetate.
Di Silverio F; Sciarra F; D'Eramo G
Eur Urol; 1990; 18(1):10-5. PubMed ID: 2144819
[TBL] [Abstract][Full Text] [Related]
11. Two-monthly depot gonadotropin releasing hormone agonist (buserelin) for treatment of prostatic cancer.
Waxman JH; Sandow J; Abel P; Farah N; O'Donoghue EP; Fleming J; Cox J; Sikora K; Williams G
Acta Endocrinol (Copenh); 1989 Mar; 120(3):315-8. PubMed ID: 2494825
[TBL] [Abstract][Full Text] [Related]
12. Zoladex vs. Zoladex plus cyproterone acetate in the treatment of advanced prostatic cancer: a multicenter Italian study.
Di Silverio F; Serio M; D'Eramo G; Sciarra F
Eur Urol; 1990; 18 Suppl 3():54-61. PubMed ID: 2151278
[TBL] [Abstract][Full Text] [Related]
13. Testicular changes after treatment with a GnRH analog (buserelin) in association with cyproterone acetate in men with prostatic cancer.
Properzi G; Francavilla S; Vicentini C; Cordeschi G; Galassi P; Paradiso Galatioto G; Miano L
Eur Urol; 1989; 16(6):426-32. PubMed ID: 2531668
[TBL] [Abstract][Full Text] [Related]
14. A multicenter randomized trial comparing the luteinizing hormone-releasing hormone analogue goserelin acetate alone and with flutamide in the treatment of advanced prostate cancer. The International Prostate Cancer Study Group.
Tyrrell CJ; Altwein JE; Klippel F; Varenhorst E; Lunglmayr G; Boccardo F; Holdaway IM; Haefliger JM; Jordaan JP
J Urol; 1991 Nov; 146(5):1321-6. PubMed ID: 1834864
[TBL] [Abstract][Full Text] [Related]
15. The first clinical use of depot buserelin for advanced prostatic carcinoma.
Waxman JH; Sandow J; Man A; Barnett MJ; Hendry WF; Besser GM; Oliver RT; Magill PJ
Cancer Chemother Pharmacol; 1986; 18(2):174-5. PubMed ID: 3098445
[TBL] [Abstract][Full Text] [Related]
16. Luteinizing hormone-releasing hormone agonists in prostate cancer. Elimination of flare reaction by pretreatment with cyproterone acetate and low-dose diethylstilbestrol.
Bruchovsky N; Goldenberg SL; Akakura K; Rennie PS
Cancer; 1993 Sep; 72(5):1685-91. PubMed ID: 7688656
[TBL] [Abstract][Full Text] [Related]
17. The combination of cyproterone acetate and low dose diethylstilbestrol in the treatment of advanced prostatic carcinoma.
Goldenberg SL; Bruchovsky N; Rennie PS; Coppin CM
J Urol; 1988 Dec; 140(6):1460-5. PubMed ID: 2973529
[TBL] [Abstract][Full Text] [Related]
18. Simultaneous administration of a luteinizing hormone releasing hormone agonist and diethylstilbestrol in the initial treatment of prostatic cancer.
Mahler C; Denis L
Am J Clin Oncol; 1988; 11 Suppl 2():S127-8. PubMed ID: 2977268
[TBL] [Abstract][Full Text] [Related]
19. Cyproterone acetate lead-in prevents initial rise of serum testosterone induced by luteinizing hormone-releasing hormone analogs in the treatment of metastatic carcinoma of the prostate.
Boccon-Gibod L; Laudat MH; Dugue MA; Steg A
Eur Urol; 1986; 12(6):400-2. PubMed ID: 2949980
[TBL] [Abstract][Full Text] [Related]
20. Effectiveness of cyproterone acetate in achieving castration and preventing luteinizing hormone releasing hormone analogue induced testosterone surge in patients with prostate cancer.
Appu S; Lawrentschuk N; Grills RJ; Neerhut G
J Urol; 2005 Jul; 174(1):140-2. PubMed ID: 15947599
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
